Results 81 to 90 of about 535,272 (262)

Real‐World Safety and Effectiveness of JAK Inhibitors in Systemic Sclerosis: A Propensity‐Matched Study From the EUSTAR Cohort

Arthritis Care &Research, EarlyView.
Objective JAK inhibitors (JAKi) have shown promising effects in early‐phase studies of systemic sclerosis (SSc). We aimed to assess the safety and explore the effectiveness of JAKi compared to conventional immunosuppressants in SSc. Methods A longitudinal retrospective study of the European Scleroderma Trials and Research Group (EUSTAR) cohort was ...
Stefano Di Donato, Marie‐Elise Truchetet, Marco Minerba, Oliver Distler, Juan José Alegre Sancho, Yolanda Braun‐Moscovici, Christina Bergmann, Petros Sfikakis, Jeska K. de Vries‐Bouwstra, Murray Baron, Silvia Bellando‐Randone, Lorenzo Dagna, Christopher P. Denton, Madelon C. Vonk, Vanessa Smith, Ivan Castellvi, Gabriela Riemekasten, Andra Balanescu, Masataka Kuwana, Maria De Santis, Kamal Solanki, Anastas Batalov, Vahan Mukuchyan, Marco Matucci‐Cerinic, Yannick Allanore, Francesco Del Galdo, Michael Hughes, EUSTAR Collaborators   +27 more
wiley   +1 more source

Therapeutic Mode of Action of Methotrexate

Central Asian Journal of Medical Sciences, 2016
Objectives: Methotrexate (MTX) has been used in clinical practice for over a half-century and its action mechanism is believed to rely on the direct inhibition of DNA synthesis leading to suppression of cell proliferation.
Dashlkhumbe Byamba, Do-Young Kim, Chimidtseren Soodoi, Enkhtur Yadamsuren, Ariunaa Munkhbayar, Nandintsetseg Batbayar, Dashkhajidmaa Dashdondov, Oyuntsatsral Batsaikhan, Batbaatar Gunchin, Min-Geol Lee   +9 more
doaj   +1 more source

From Adult to Adolescent: Alignment in Clinical Trials and Outcomes in Axial Spondyloarthritis

Arthritis Care &Research, EarlyView.
Spondyloarthritis (SpA) is a group of chronic inflammatory diseases encompassing axial and peripheral forms, with up to 20% of patients developing symptoms before age 16. Despite this substantial pediatric burden, treatment options for juvenile‐onset SpA (JSpA), particularly those with axial disease (axJSpA), remain limited.
Pamela F. Weiss, Judith A. Smith, Robert A. Colbert, Erin Treemarcki, Michael H. Weisman, Walter P. Maksymowych, Hermine I. Brunner, for the Childhood Arthritis and Rheumatology Research Alliance, Spondyloarthritis Research and Treatment Network, and Pediatric Rheumatology Collaborative Study Group Advisory Council   +9 more
wiley   +1 more source

The Role of IL-23 in the Development of Inflammatory Diseases

Biology
Interleukin-23 is crucial in the initiation and progression of certain inflammatory disorders. As a key cytokine, IL-23 is involved in the differentiation and activation of Th17 cells, which play a role in a broad spectrum of inflammatory diseases.
Mario García-Domínguez
doaj   +1 more source

Short‐term response to biologic therapy in psoriatic arthritis (PsA) is not influenced by disease duration at initiation of therapy

Arthritis Care &Research, Accepted Article.
Objectives We aimed to determine whether the short‐term response to biologics in biologic‐naïve psoriatic arthritis (PsA) is better in patients initiating biologic treatment early in the disease course. Methods PsA patients who started biologic therapy from the year 2000 to 2025 were included for analysis. Patients considered in the early treatment (ET)
Sung Min Cho, Shangyi Gao, Daniel Pereira, Richard J. Cook, Dafna D. Gladman   +4 more
wiley   +1 more source

Impact of Six‐Month Monitoring Compared to Three‐Month Monitoring of Laboratories During Methotrexate Therapy

Arthritis Care &Research, EarlyView.
Objective To evaluate whether extending the American College of Rheumatology–recommended monitoring interval for complete blood count and liver function tests in patients receiving methotrexate (MTX) affects timely detection of medication‐related toxicity.
Spencer Simko, Ray Zhang, Sohini Mukherjee, Puneet Bajaj, Bonnie L. Bermas   +4 more
wiley   +1 more source

The IL-23/IL-17 axis in Behçet’s syndrome pathogenesis: from immunological perspectives to therapeutic implications

Frontiers in Immunology
Behçet’s Syndrome (BS) is a systemic vasculitis characterized by variable vessel involvement and an elusive etiology, though immunogenetic studies strongly implicate the IL-23/IL-17 axis which bridges innate and adaptive immunity, orchestrating type 17 T-
Mohammad E. Naffaa, Mohammad E. Naffaa, Fadi Hassan, Fadi Hassan, Mahmud Omar, Mahmud Omar, Kerem Abacar, Dennis McGonagle   +7 more
doaj   +1 more source

Strain‐Programmable Luminescent Adhesive Patch With Tartrazine‐Mediated Optical Skin Clearing for Photochemical Tissue Bonding

Advanced Functional Materials, EarlyView.
We propose a suture‐complementary approach that integrates optical skin clearing with a strain‐programmable luminescent adhesive patch. Hyaluronic acid promotes transdermal delivery of tartrazine to improve optical clearing and stabilizes its interaction with a photosensitizer. Optical clearing increases the penetration depth of visible light into skin,
Seong‐Jong Kim, Kyungjoo Jo, Kwanghyeon Park, Jun Hee Kim, Jong Hyeong Cho, Inhoo Choi, Sei Kwang Hahn   +6 more
wiley   +1 more source

Pull‐and‐Push Nanotherapeutic Hydrogels: Scavenging Inflammatory Triggers While Driving Tissue Regeneration in Burn Wounds

Advanced Functional Materials, EarlyView.
A nanounit‐assembled hydrogel employing a “pull‐and‐push” strategy simultaneously scavenges pro‐inflammatory cell‐free DNA (cfDNA) and delivers regenerative therapeutics in response to burn‐induced hyperthermia. By repolarizing macrophages and promoting angiogenesis, this multifunctional platform accelerates burn wound healing, offering a blueprint for
Han‐Sem Kim, Seong‐Jin Shin, Sak Lee, Nandin Mandakhbayar, Ji‐Hye Kang, Da‐Young Kong, Seong‐Doo Hong, Ueon Sang Shin, Hae‐Won Kim, Jung‐Hwan Lee   +9 more
wiley   +1 more source

Gellan Gum Fluid Gel System for Controlled‐Delivery of Cytokine‐Licensed MSC‐EVs to Enhance Corneal Repair in Limbal Stem Cell Deficiency

Advanced Healthcare Materials, EarlyView.
Gellan gum fluid gel (FG) enables controlled ocular delivery of mesenchymal stromal cell (MSC)‐derived extracellular vesicles (EV). Its shear‐thinning, solid‐liquid‐solid rheology ensures prolonged ocular retention. Sustained MSC‐EV release (∼18% in 6 hrs) supports effective EV ocular delivery.
Seyedmohammad Moosavizadeh, Ava Dashti, Thomas E. Robinson, Robyn Gaffey, Richard Moakes, Neil Lagali, Liam Grover, Thomas Ritter   +7 more
wiley   +1 more source